Gastric Inhibitory Polypeptide: the neglected incretin revisited
Tóm tắt
Từ khóa
Tài liệu tham khảo
Moore, 1906, On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane, Biochem. J., 1, 28, 10.1042/bj0010028
Dupré, 1966, Stimulation of release of insulin by an extract of intestinal mucosa, Diabetes, 15, 555, 10.2337/diab.15.8.555
Kosaka, 1930, Demonstration of the humoral agent in fat inhibition on gastric secretion, Proc. Soc. Exp. Biol. Med., 27, 890, 10.3181/00379727-27-5024
Brown, 1969, Preparation of highly active enterogastrone, Can. J. Physiol. Pharmacol., 47, 113, 10.1139/y69-020
Brown, 1970, Further purification of a polypeptide demonstrating enterogastrone activity, J. Physiol., 209, 57, 10.1113/jphysiol.1970.sp009155
Brown, 1971, A gastric inhibitory polypeptide II. The complete amino acid sequence, Can. J. Biochem., 49, 867, 10.1139/o71-122
Pederson, 1972, Inhibition of histamine-, pentagastrin-, and insulin-stimulated canine gastric secretion by pure ‘gastric inhibitory polypeptide’, Gastroenterology, 62, 393, 10.1016/S0016-5085(72)80144-6
Maxwell, 1980, Effect of gastric inhibitory polypeptide on pentagastrin-stimulated acid secretion in man, Dig. Dis. Sci., 24, 113, 10.1007/BF01308308
Elrick, 1964, Plasma insulin response to oral and intravenous glucose administration, J. Clin. Endocrinol. Metab., 24, 1076, 10.1210/jcem-24-10-1076
McIntyre, 1965, Intestinal factors in the control of insulin secretion, J. Clin. Endocrinol., 25, 1317, 10.1210/jcem-25-10-1317
Pederson, 1975, Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog, Diabetes, 24, 1050, 10.2337/diabetes.24.12.1050
Pederson, 1976, The insulinotropic action of gastric inhibitory polypeptide in the perfused rat pancreas, Endocrinology, 99, 780, 10.1210/endo-99-3-780
Pederson, 1978, Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secreton from the perfused rat pancreas, Endocrinology, 103, 610, 10.1210/endo-103-2-610
Dupré, 1973, Stimulation of insulin secretion by gastric inhibitory polypeptide in man, J. Clin. Endocrinol. Metab., 37, 826, 10.1210/jcem-37-5-826
Andersen, 1978, Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels, J. Clin. Invest., 62, 152, 10.1172/JCI109100
Elahi, 1979, Pancreatic α- and β-cell responses to GIP infusion in normal man, Am. J. Physiol., 237, E185
Creutzfeldt, 1985, New developments in the incretin concept, Diabetologia, 28, 565, 10.1007/BF00281990
Brown, 1976, GI hormones and insulin secretion. Endocrinology, Proc. Int. Congr. Endocrinol., 5th, 2, 568
Ross, 1977, Hypersecretion of gastric inhibitory polypeptide following oral glucose in diabetes mellitus, Diabetes, 26, 525, 10.2337/diabetes.26.6.525
Ross, 1978, Effects of ingestion of triglyceride or galactose on secretion of Gastric Inhibitory Polypeptide and on response to intravenous glucose in normal and diabetic subjects, Diabetes, 27, 327, 10.2337/diabetes.27.3.327
May, 1978, The effect of endogenous Gastric Inhibitory Polypeptide on glucose-induced insulin secretion in mild diabetes, Diabetes, 27, 849, 10.2337/diab.27.8.849
Krarup, 1988, Effect of porcine gastric inhibitory polypeptide on β-cell function in Type 1 and Type II diabetes mellitus, Metabolism, 36, 677, 10.1016/0026-0495(87)90153-3
Amland, 1985, Effects of intravenously infused porcine GIP on serum insulin, plasma C-peptide, and pancreatic polypeptide in non-insulin-dependent diabetes in the fasting state, Scand. J. Gastroenterol., 20, 315, 10.3109/00365528509091657
Jorde, 1987, The insulinotropic effect of gastric inhibitory polypeptide in non-insulin dependent diabetes, Ital. J. Gastroenterol., 19, 76
Jones, 1988, Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in Type 2 (noninsulin-dependent) diabetes mellitus, Horm. Metab. Res., 21, 23, 10.1055/s-2007-1009141
Nauck, 1993, Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus, J. Clin. Invest., 91, 301, 10.1172/JCI116186
Meier, 2001, Reduced insulinotropic effect of Gastric Inhibitory Polypeptide in first-degree relatives of patients with type 2 diabetes, Diabetes, 50, 2497, 10.2337/diabetes.50.11.2497
Göke, 1989, Signal transmission after GLP-1(7–36)amide binding in RINm5F cells, Am. J. Physiol., 257, G397
Gallwitz, 1996, GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1, Regul. Pept., 63, 17, 10.1016/0167-0115(96)00019-5
Polak, 1973, Cellular localization of gastric inhibitory polypeptide in the duodenum and jejunum, Gut, 14, 284, 10.1136/gut.14.4.284
Buffa, 1975, Identification of the intestinal cell storing gastric inhibitory polypeptide, Histochemistry, 43, 249, 10.1007/BF00499706
Thomas, 1977, Localization of gastric inhibitory polypeptide release by intestinal glucose perfusion in man, Gastroenterology, 72, 49, 10.1016/S0016-5085(77)80302-8
Buchan, 1978, Electron immunocytochemical evidence of the K cell localisation of gastric inhibitory polypeptide (GIP) in man, Histochemistry, 56, 37, 10.1007/BF00492251
Ørskov, 1986, Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas, Endocrinology, 119, 1467, 10.1210/endo-119-4-1467
Eissele, 1992, Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man, Eur. J. Clin. Invest., 22, 283, 10.1111/j.1365-2362.1992.tb01464.x
Mortensen, 2000, Colocalisation of GLP-1 and GIP in human and porcine intestine, Ann. N. Y. Acad. Sci., 921, 469, 10.1111/j.1749-6632.2000.tb07017.x
Mortensen, 2001, The incretin hormones GLP-1 and GIP are partly colocalized in the gut in man, pig and rat (abstract), Diabetes, 50, A311
Cataland, 1974, Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man, J. Clin. Endocrinol. Metab., 39, 223, 10.1210/jcem-39-2-223
Falko, 1975, Gastric Inhibitory Polypeptide (GIP) stimulated by fat ingestion in man, J. Clin. Endocrinol. Metab., 41, 260, 10.1210/jcem-41-2-260
Imeryuz, 1997, Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms, Am. J. Physiol., 273, G920
Cheung, 2000, Glucose-dependent insulin release from genetically engineered K cells, Science, 290, 1959, 10.1126/science.290.5498.1959
Nauck, 2001, Quantification of the incretin effect in first-degree relatives of type 2 diabetic patients compared to healthy control subjects (abstract), Diabetologia, 44, A195
Damholdt, 1998, Glucagon-like peptide-1 secretion from canine L-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose, Endocrinology, 139, 2085, 10.1210/en.139.4.2085
Damholdt, 1999, Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine, Cell Tissue Res., 298, 287, 10.1007/s004419900093
Schmidt, 1987, Commercially available preparations of porcine glucose-dependent insulinotropic polypeptide (GIP) contain a biologically inactive GIP-fragment and cholezystokinin-33/-39, Endocrinology, 120, 835, 10.1210/endo-120-2-835
Mentlein, 1993, Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum, Eur. J. Biochem., 214, 829, 10.1111/j.1432-1033.1993.tb17986.x
Deacon, 2000, Degradation of endogenous and exogenous Gastric Inhibitory Polypeptide (GIP) in healthy and in Type 2 diabetic subjects as revealed using a new assay for the intact peptide, J. Clin. Endocrinol. Metab., 85, 3575, 10.1210/jc.85.10.3575
Kieffer, 1995, Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV, Endocrinology, 136, 3585, 10.1210/en.136.8.3585
Mentlein, 1999, Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides, Regul. Pept., 85, 9, 10.1016/S0167-0115(99)00089-0
Jörnvall, 1981, Amino acid sequence and heterogeneity of gastric inhibitory polypeptide (GIP), FEBS Lett., 123, 205, 10.1016/0014-5793(81)80288-8
Gallwitz, 1995, Binding characteristics of N-terminal GIP/GLP-1 hybrid peptides, Endocrinol. Metab., 2, 39
Sarson, 1982, The pharmacokinetics of porcine glucose-dependent insulinotropic polypeptide (GIP) in man, Eur. J. Clin. Invest., 12, 457, 10.1111/j.1365-2362.1982.tb02224.x
Nauck, 1989, Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man; interactions with glucose, phenylalanine, and cholezystokinin-8, J. Clin. Endocrinol. Metab., 69, 654, 10.1210/jcem-69-3-654
Pauly, 1999, Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide, Metabolism, 48, 385, 10.1016/S0026-0495(99)90090-2
Deacon, 2001, Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic effects in anesthetized pigs, Diabetes, 50, 1588, 10.2337/diabetes.50.7.1588
Marguet, 2000, Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26, Proc. Natl. Acad. Sci., 97, 6874, 10.1073/pnas.120069197
Sirinek, 1984, Chronic renal failure: effect of hemodialysis on gastrointestinal hormones, Am. J. Surg., 148, 732, 10.1016/0002-9610(84)90426-4
O'Doriso, 1977, Renal effects on serum gastric inhibitory polypeptide (GIP), Metabolism, 26, 651, 10.1016/0026-0495(77)90086-5
Ørskov, 1992, All products of proglucagon are elevated in plasma of uremic patients, J. Clin. Endocrinol. Metab., 74, 379, 10.1210/jc.74.2.379
Jorde, 1981, Removal of IR-GIP by the kidneys in man, and the effect of acute nephrectomy on plasma GIP in rats, Scand. J. Gastroenterol., 16, 469, 10.3109/00365528109182000
Hanks, 1984, The hepatic extraction of gastric inhibitory polypeptide and insulin, Endocrinology, 115, 1011, 10.1210/endo-115-3-1011
Chap, 1987, Absence of hepatic extraction of gastric inhibitory polypeptide in conscious dogs, Dig. Dis. Sci., 32, 280, 10.1007/BF01297054
Ebert, 1979, Impaired feedback control of fat induced gastric inhibitory polypeptide (GIP) secretion by insulin in obesity and glucose intolerance, Eur. J. Clin. Invest., 9, 129, 10.1111/j.1365-2362.1979.tb01678.x
Creutzfeldt, 1978, Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels, Diabetologia, 14, 15, 10.1007/BF00429703
Salera, 1982, Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus and obesity, J. Clin. Endocrinol. Metab., 55, 329, 10.1210/jcem-55-2-329
Elahi, 1984, The enteric enhancement of glucose-stimulated insulin release: the role of GIP in aging, obesity, and non-insulin-dependent diabetes mellitus, Diabetes, 33, 950, 10.2337/diabetes.33.10.950
Flatt, 1983, Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice, Diabetes, 32, 433, 10.2337/diabetes.32.5.433
Service, 1984, Gastric inhibitory polypeptide in obesity and diabetes mellitus, J. Clin. Endocrinol. Metab., 58, 1133, 10.1210/jcem-58-6-1133
Osei, 1986, Gastric Inhibitory Polypeptide responses and glucose turnover rates after natural meals in type II diabetic patients, J. Clin. Endocrinol. Metab., 62, 325, 10.1210/jcem-62-2-325
Mazzaferri, 1985, Gastric inhibitory polypeptide responses to nutrients in Caucasians and American Indians with obesity and non-insulin-dependent diabetes mellitus, J. Clin. Endocrinol. Metab., 61, 313, 10.1210/jcem-61-2-313
Krarup, 1988, Immunoreactive gastric inhibitory polypeptide, Endocr. Rev., 9, 122, 10.1210/edrv-9-1-122
Vilsbøll, 2001, Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients, Diabetes, 50, 609, 10.2337/diabetes.50.3.609
Eckel, 1979, Gastric inhibitory polypeptide enhance lipoprotein lipase activity in cultured preadipocytes, Diabetes, 28, 1141, 10.2337/diabetes.28.12.1141
Knapper, 1995, Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1(7–36)amide on lipoprotein lipase activity in explants of rat adipose tissue, J. Nutr., 125, 183
Beck, 1983, Gastric inhibitory polypeptide enhancement of the insulin effect on fatty acid incorporation into adipose tissue in the rat, Regul. Pept., 7, 3, 10.1016/0167-0115(83)90276-8
Beck, 1987, Hypersensitivity of adipose tissue to gastric inhibitory polypeptide action in obese Zucker rat, Cell. Mol. Biol., 33, 555
Oben, 1991, Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7–36) amide, on fatty acid synthesis in explants of rat adipose tissue, J. Endocrinol., 130, 267, 10.1677/joe.0.1300267
Dupré, 1976, Inhibition of action of glucagon in adipocytes by gastric inhibitory polypeptide, Metabolism, 25, 1197, 10.1016/S0026-0495(76)80002-9
Hauner, 1988, Effects of gastric inhibitory polypeptide on glucose and lipid metabolism of isolated rat adipocytes, Ann. Nutr. Metab., 32, 282, 10.1159/000177467
Usdin, 1993, Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain, Endocrinology, 133, 2861, 10.1210/en.133.6.2861
Yip, 1998, Functional GIP receptors are present on adipocytes, Endocrinology, 139, 4004, 10.1210/en.139.9.4004
Tsubamoto, 2001, The effect of gastric inhibitory polypeptide on 3T3-L1 adipocytes (abstract), Diabetologia, 44, A195
Wasada, 1981, Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs, J. Clin. Invest., 68, 1107, 10.1172/JCI110335
Ohneda, 1983, Effect of endogenous gastric inhibitory polypeptide (GIP) on the removal of triacylglycerol in dogs, Regul. Pept., 6, 25, 10.1016/0167-0115(83)90131-3
Ebert, 1991, Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride response in rats, Horm. Metab. Res., 23, 517, 10.1055/s-2007-1003745
Yki-Järvinen, 1984, Response of adipose tissue lipoprotein lipase activity and serum lipoproteins to acute hyperinsulinaemia in men, Diabetologia, 27, 364, 10.1007/BF00304851
Miyawaki, 2001, Inhibition if GIP/GIPR axis prevents obesity (abstract), Diabetologia, 44, A18
Jorde, 1984, Lack of effect of exogenous or endogenous gastric inhibitory polypeptide on the elimination rate of intralipid in man, Acta Med. Scand., 216, 19, 10.1111/j.0954-6820.1984.tb03765.x
Yamagishi, 1980, Gastric inhibitory polypeptide (GIP) is not the primary mediator of the enterogastrone action of fat in the dog, Gastroenterology, 78, 931, 10.1016/0016-5085(80)90774-X
Nauck, 1992, Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7–36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects, Digestion, 52, 214, 10.1159/000200956
Wettergren, 1993, Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man, Dig. Dis. Sci., 38, 665, 10.1007/BF01316798
Nauck, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am. J. Physiol., 273, E981
Creutzfeldt, 1992, Gut hormones and diabetes mellitus, Diabetes/Metab. Rev., 8, 149, 10.1002/dmr.5610080206
Siegel, 1992, Comparison of the effect of GIP and GLP-1 (7–36amide) on insulin release from rat pancreatic islets, Eur. J. Clin. Invest., 22, 154, 10.1111/j.1365-2362.1992.tb01820.x
Elahi, 1982, Interaction of arginine and gastric inhibitory polypeptide on insulin release in man, Am. J. Physiol., 242, E343
Nauck, 1986, Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses, J. Clin. Endocrinol. Metab., 63, 492, 10.1210/jcem-63-2-492
Kreymann, 1987, Glucagon-like peptide-1 [7–36]: a physiological incretin in man, Lancet, 2, 1300, 10.1016/S0140-6736(87)91194-9
Nauck, 1993, Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations, J. Clin. Endocrinol. Metab., 76, 912, 10.1210/jc.76.4.912
Jones, 1987, The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion, Diabetologia, 30, 707, 10.1007/BF00296993
Lauritsen, 1981, Depression of insulin release by Anti-GIP serum after oral glucose in rats, Scand. J. Gastroenterol., 16, 417, 10.3109/00365528109181990
Tseng, 1996, Postprandial stimulation of insulin release by glucose-dependent insulinotropic peptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat, J. Clin. Invest., 98, 2440, 10.1172/JCI119060
Tseng, 1999, Effect of GIP and GLP-1 antagonists on insulin release in the rat, An. J. Physiol., 276, E1049
Miyawaki, 1999, Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice, Proc. Natl. Acad. Sci., 96, 14843, 10.1073/pnas.96.26.14843
Trumper, 2001, Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling, Mol. Endocrinol., 15, 1559, 10.1210/me.15.9.1559
Zhou, 1999, Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells, Diabetes, 48, 2358, 10.2337/diabetes.48.12.2358
Stoffers, 2000, Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas, Diabetes, 49, 741, 10.2337/diabetes.49.5.741
Nauck, 1986, Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes, Diabetologia, 29, 46, 10.1007/BF02427280
Ørskov, 1993, Biological effects and metabolic rates of glucagonlike peptide-1 7–36 amide and glucagonlike peptide-1 7–37 in healthy subjects are indistinguishable, Diabetes, 42, 658, 10.2337/diabetes.42.5.658
Dupré, 1991, Stimulation of glucagon secretion by gastric inhibitory polypeptide in patients with hepatic cirrhosis and hyperglucagonemia, J. Clin. Endocrinol. Metab., 72, 125, 10.1210/jcem-72-1-125
Kindmark, 2001, Glucose-dependent insulinotropic hormone potentiates the hypoglycemic effect of glibenclamide in healthy volunteers: evidence for an effect on insulin extraction, J. Clin. Endocrinol. Metab., 2015, 10.1210/jc.86.5.2015
Madsbad, 1983, Discrepancy between plasma C-peptide and insulin response to oral and intravenous glucose, Diabetes, 32, 436, 10.2337/diabetes.32.5.436
Tseng, 1996, Chronic desensitization of the glucose-dependent insulinotropic polypeptide receptor in diabetic rats, Am. J. Physiol., 270, E661
Ebert, 1980, Hypo- and hypersecretion of GIP in maturity-onset diabetics (abstract), Diabetologia, 19, 271
Tseng, 1998, Role of regulator of G protein signalling in desensitization of the glucose-dependent insulinotrpic peptide receptor, Endocrinology, 139, 4470, 10.1210/en.139.11.4470
Tseng, 1998, The cysteine of the cytoplasmatic tail of glucose-dependent insulinotropic peptide receptor mediates its chronic desensitisation and down-regulation, Mol. Cell. Endocrinol., 139, 179, 10.1016/S0303-7207(98)00061-6
Hinke, 2000, Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (βTC-3) cells to glucose-dependent insulinotropic polypeptide, J. Endocrinol., 165, 281, 10.1677/joe.0.1650281
Nauck, 1997, Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for Type 2-diabetes, Exp. Clin. Endocrinol. Diabetes, 105, 187, 10.1055/s-0029-1211750
Holst, 2000, Gut hormones as pharmaceuticals: from enteroglucagon to GLP-1 and GLP-2, Regul. Pept., 93, 45, 10.1016/S0167-0115(00)00185-3
Holst, 1997, The pathogenesis of NIDDM involvers a defective expression of the GIP receptor, Diabetologia, 40, 984, 10.1007/s001250050779
Kubota, 1996, Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDM: no evidence of association with Japanese NIDDM subjects, Diabetes, 45, 1701, 10.2337/diabetes.45.12.1701
Amlind, 1998, Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell response and functional expression studies in Chinese hamster fibroblast cells, Diabetologia, 41, 1194, 10.1007/s001250051051
Lynn, 2001, Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats, Diabetes, 50, 1004, 10.2337/diabetes.50.5.1004
Köbberling, 1985, Genetics of type 2A- and type 2B-Diabetes mellitus (abstract), Diabetes Res. Clin. Pract., 1, 311
Eriksson, 1989, Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus, N. Engl. J. Med., 10, 337, 10.1056/NEJM198908103210601
Weyer, 1999, The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus, J. Clin. Invest., 104, 787, 10.1172/JCI7231
Fritsche, 2000, Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion, Diabetologia, 43, 852, 10.1007/s001250051461
Pratley, 2001, The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus, Diabetologia, 44, 929, 10.1007/s001250100580
Holz, 1993, Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7–37), Nature, 361, 362, 10.1038/361362a0
Scrocchi, 1996, Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene, Nat. Med., 2, 1254, 10.1038/nm1196-1254
Holst, 1987, Truncated glucagon-like peptide 1, an insulin-releasing hormone from the distal gut, FEBS Lett., 211, 169, 10.1016/0014-5793(87)81430-8
Nathan, 1992, Insulinotropic action of glucagon-like peptide 1 (7–37) in diabetic and non-diabetic subjects, Diabetes Care, 15, 270, 10.2337/diacare.15.2.270
Flint, 1998, Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans, J. Clin. Invest., 101, 515, 10.1172/JCI990
Gutzwiller, 1997, Glucagon-like peptide-1 is a physiologic regulator of food intake in humans, Gastroenterol., 112, A1153
Gutzwiller, 1999, Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2, Am. J. Physiol., 276, R1541
Nauck, 1993, Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients, Diabetologia, 36, 741, 10.1007/BF00401145
Turton, 1996, A role for glucagon-like peptide-1 in the central regulation of feeding, Nature, 379, 69, 10.1038/379069a0
Donahey, 1998, Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats, Brain Res., 229, 75, 10.1016/S0006-8993(97)01057-3
Meeran, 1999, Repeated intracerebroventricular administration of Glucagon-like Peptide-1-(7–36) amide or exendin-(9–39) alters body weight in the rat, Endocrinology, 140, 244, 10.1210/en.140.1.244
Hansen, 2001, Sustained appetite suppression and weight loss in obese rhesus monkeys treated with a long-acting GLP-1 derivate, NN2211 (abstract), Diabetologia, 44, A196
Larsen, 2001, Systemic administration of the long-acting GLP-1 analogue, NN2211, induces lasting and reversible loss of body obesity (abstract), Diabetologia, 43, A144
Sturis, 2001, Long-acting GLP-1 derivate NN2211 markedly attenuates diabetes development in the male Zucker diabetic fatty rat (abstract), Diabetologia, 43, A145
Holst, 1998, Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes, Diabetes, 47, 1663, 10.2337/diabetes.47.11.1663
Pederson, 1998, Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidine, Diabetes, 47, 1253, 10.2337/diabetes.47.8.1253
Lin, 1998, Inhibition of dipeptidyl-peptidase IV by fluoroolefin-containing N-peptidyl-O-hydroxylamine peptidomimetics, Proc. Natl. Acad. Sci., 95, 14020, 10.1073/pnas.95.24.14020
Balkan, 1999, Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7–36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats, Diabetologia, 42, 1324, 10.1007/s001250051445
Ahren, 2000, Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice, Eur. J. Pharmacol., 404, 239, 10.1016/S0014-2999(00)00600-2
Creutzfeldt, 2001, The entero-insular axis in type 2 diabetes—incretins as therapeutic agents, Exp. Clin. Endocrinol. Diabetes, 109, 288, 10.1055/s-2001-18589
O'Harte, 1998, Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells, Biochim. Biophys. Acta, 1425, 319, 10.1016/S0304-4165(98)00084-1
O'Harte, 1999, NH2-terminally modified Gastric Inhibitory Polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity, Diabetes, 48, 758, 10.2337/diabetes.48.4.758
O'Harte, 2000, Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide, J. Endocrinol., 165, 639, 10.1677/joe.0.1650639
O'Harte, 2001, DPP IV resistant N-terminally modified GIP analogues with enhanced insulinotropic activity (abstract), Diabetologia, 44, A194
Gault, 2001, GIP analogues substituted at Ala2 exhibit improved plasma stability and insulin-releasing activity (abstract), Diabetologia, 44, A195
Tseng, 1994, Regulation of glucose-dependent insulinotropic peptide gene expression by a glucose meal, Am. J. Physiol., 266, G887
Kieffer, 1994, Release of gastric inhibitory polypeptide from cultured canine endocrine cells, Am. J. Physiol., 267, E489
Kieffer, 1995, Gastric inhibitory polypeptide release from a tumor derived cell line, Am. J. Physiol., 269, E316
Wang, 1997, Modulation of glucose responsiveness of insulinoma beta-cells by graded overexpression of glucokinase, Proc. Natl. Acad. Sci., 94, 4372, 10.1073/pnas.94.9.4372
Ramiya, 2000, Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells, Nat. Med., 6, 278, 10.1038/73128
Pfeiffer, 2000, Current perspectives of biotechnological replacement of insulin secreting cells, Exp. Clin. Endocrinol. Diabetes, 108, 494, 10.1055/s-2000-11002
Thule, 2000, Regulated hepatic insulin gene therapy of STZ-diabetic rats, Gene Ther., 7, 1744, 10.1038/sj.gt.3301297
Ørskov, 1988, Effect of truncated glucagon-like peptide-1 [proglucagon-(78–107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach, Endocrinology, 123, 2009, 10.1210/endo-123-4-2009
Tolessa, 1998, Inhibitory effect of Glucagon-like peptide-1 on small bowel motility, J. Clin. Invest., 102, 764, 10.1172/JCI942
Zander, 2001, GLP-1 for six weeks reduces body weight and improves insulin sensitivity and glycemic control in patients with Type 2 diabetes, Diabetes, 50, A31